Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-hodgkin's lymphoma

Leo I. Gordon, Thomas E. Witzig, Greg A. Wiseman, Ian W. Flinn, Stewart S. Spies, Daniel H. Silverman, Christos Emmanuolides, Larry Cripe, Mansoor Saleh, Myron S. Czuczman, Teresa Olejnik, Christine A. White, Antonio J. Grillo-López

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

The treatment of malignant lymphoma has improved over the past 20 years, but the majority of patients are not cured. New modalities using targeted therapy based on new information in molecular biology and immunology hold promise for better outcomes with less toxicity. We review data on the use of radiolabeled monoclonal antibodies directed against the CD20 antigen on malignant B cells. We discuss the major radionuclides available, iodine 131 (131I), tositumomab, and yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals, San Diego, CA) and present data on new approaches in labeling antibodies that have facilitated their use. Clinical trial data with the yttrium-labeled antibodies are discussed. The use of dosimetry as a means for predicting toxicity is discussed, and the questions of long-term toxicity (late effects) are addressed. These targeted approaches to the treatment of malignancy, and lymphoma in particular, hold great promise.

Original languageEnglish (US)
Pages (from-to)87-92
Number of pages6
JournalSeminars in Oncology
Volume29
Issue number1 SUPPL. 2
StatePublished - 2002
Externally publishedYes

Fingerprint

Radioimmunotherapy
Non-Hodgkin's Lymphoma
Lymphoma
CD20 Antigens
Yttrium
Antibodies
Allergy and Immunology
Radioisotopes
Molecular Biology
B-Lymphocytes
Therapeutics
Monoclonal Antibodies
Clinical Trials
Pharmaceutical Preparations
ibritumomab tiuxetan
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Gordon, L. I., Witzig, T. E., Wiseman, G. A., Flinn, I. W., Spies, S. S., Silverman, D. H., ... Grillo-López, A. J. (2002). Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-hodgkin's lymphoma. Seminars in Oncology, 29(1 SUPPL. 2), 87-92.

Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-hodgkin's lymphoma. / Gordon, Leo I.; Witzig, Thomas E.; Wiseman, Greg A.; Flinn, Ian W.; Spies, Stewart S.; Silverman, Daniel H.; Emmanuolides, Christos; Cripe, Larry; Saleh, Mansoor; Czuczman, Myron S.; Olejnik, Teresa; White, Christine A.; Grillo-López, Antonio J.

In: Seminars in Oncology, Vol. 29, No. 1 SUPPL. 2, 2002, p. 87-92.

Research output: Contribution to journalArticle

Gordon, LI, Witzig, TE, Wiseman, GA, Flinn, IW, Spies, SS, Silverman, DH, Emmanuolides, C, Cripe, L, Saleh, M, Czuczman, MS, Olejnik, T, White, CA & Grillo-López, AJ 2002, 'Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-hodgkin's lymphoma', Seminars in Oncology, vol. 29, no. 1 SUPPL. 2, pp. 87-92.
Gordon LI, Witzig TE, Wiseman GA, Flinn IW, Spies SS, Silverman DH et al. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-hodgkin's lymphoma. Seminars in Oncology. 2002;29(1 SUPPL. 2):87-92.
Gordon, Leo I. ; Witzig, Thomas E. ; Wiseman, Greg A. ; Flinn, Ian W. ; Spies, Stewart S. ; Silverman, Daniel H. ; Emmanuolides, Christos ; Cripe, Larry ; Saleh, Mansoor ; Czuczman, Myron S. ; Olejnik, Teresa ; White, Christine A. ; Grillo-López, Antonio J. / Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-hodgkin's lymphoma. In: Seminars in Oncology. 2002 ; Vol. 29, No. 1 SUPPL. 2. pp. 87-92.
@article{66ed0ea5b70f48bd8c837e43a4983f00,
title = "Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-hodgkin's lymphoma",
abstract = "The treatment of malignant lymphoma has improved over the past 20 years, but the majority of patients are not cured. New modalities using targeted therapy based on new information in molecular biology and immunology hold promise for better outcomes with less toxicity. We review data on the use of radiolabeled monoclonal antibodies directed against the CD20 antigen on malignant B cells. We discuss the major radionuclides available, iodine 131 (131I), tositumomab, and yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals, San Diego, CA) and present data on new approaches in labeling antibodies that have facilitated their use. Clinical trial data with the yttrium-labeled antibodies are discussed. The use of dosimetry as a means for predicting toxicity is discussed, and the questions of long-term toxicity (late effects) are addressed. These targeted approaches to the treatment of malignancy, and lymphoma in particular, hold great promise.",
author = "Gordon, {Leo I.} and Witzig, {Thomas E.} and Wiseman, {Greg A.} and Flinn, {Ian W.} and Spies, {Stewart S.} and Silverman, {Daniel H.} and Christos Emmanuolides and Larry Cripe and Mansoor Saleh and Czuczman, {Myron S.} and Teresa Olejnik and White, {Christine A.} and Grillo-L{\'o}pez, {Antonio J.}",
year = "2002",
language = "English (US)",
volume = "29",
pages = "87--92",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 2",

}

TY - JOUR

T1 - Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-hodgkin's lymphoma

AU - Gordon, Leo I.

AU - Witzig, Thomas E.

AU - Wiseman, Greg A.

AU - Flinn, Ian W.

AU - Spies, Stewart S.

AU - Silverman, Daniel H.

AU - Emmanuolides, Christos

AU - Cripe, Larry

AU - Saleh, Mansoor

AU - Czuczman, Myron S.

AU - Olejnik, Teresa

AU - White, Christine A.

AU - Grillo-López, Antonio J.

PY - 2002

Y1 - 2002

N2 - The treatment of malignant lymphoma has improved over the past 20 years, but the majority of patients are not cured. New modalities using targeted therapy based on new information in molecular biology and immunology hold promise for better outcomes with less toxicity. We review data on the use of radiolabeled monoclonal antibodies directed against the CD20 antigen on malignant B cells. We discuss the major radionuclides available, iodine 131 (131I), tositumomab, and yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals, San Diego, CA) and present data on new approaches in labeling antibodies that have facilitated their use. Clinical trial data with the yttrium-labeled antibodies are discussed. The use of dosimetry as a means for predicting toxicity is discussed, and the questions of long-term toxicity (late effects) are addressed. These targeted approaches to the treatment of malignancy, and lymphoma in particular, hold great promise.

AB - The treatment of malignant lymphoma has improved over the past 20 years, but the majority of patients are not cured. New modalities using targeted therapy based on new information in molecular biology and immunology hold promise for better outcomes with less toxicity. We review data on the use of radiolabeled monoclonal antibodies directed against the CD20 antigen on malignant B cells. We discuss the major radionuclides available, iodine 131 (131I), tositumomab, and yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals, San Diego, CA) and present data on new approaches in labeling antibodies that have facilitated their use. Clinical trial data with the yttrium-labeled antibodies are discussed. The use of dosimetry as a means for predicting toxicity is discussed, and the questions of long-term toxicity (late effects) are addressed. These targeted approaches to the treatment of malignancy, and lymphoma in particular, hold great promise.

UR - http://www.scopus.com/inward/record.url?scp=0036180910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036180910&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 87

EP - 92

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 2

ER -